
European Economic Area
European Economic Area
Northern Ireland
The EU is launching an initiative in January 2025 to reduce PFAS in healthcare, focusing on sustainable alternatives and emission reduction. This project aligns with the EU's Green Deal, aiming to protect the environment and public health through collaboration and innovation.
Published in January 2025. Dates, deadlines and stages may have changed since.
2 min readAI-drafted, expert reviewed

The European Union is spearheading a new initiative to tackle the pervasive issue of per- and poly-fluoroalkyl substances (PFAS) in the healthcare sector. Launching in January 2025, this project aims to develop sustainable alternatives to PFAS, reduce emissions, and manage end-of-life disposal, aligning with the EU's Green Deal and Chemicals Strategy for Sustainability.
PFAS are widely used in healthcare products due to their durability and resistance to heat and chemicals. These substances are found in medical devices, packaging, and even in the manufacturing processes of pharmaceuticals. However, their persistence in the environment and potential health risks have raised significant concerns. The EU's initiative seeks to map PFAS applications across the healthcare supply chain and develop safer alternatives without compromising product efficacy or safety.
The initiative encourages collaboration between industry stakeholders, including pharmaceutical companies, healthcare providers, and regulatory bodies like the European Chemicals Agency (ECHA). By fostering public-private partnerships, the project aims to enhance knowledge about PFAS applications and alternatives. This collaboration will also involve testing and validating new materials to ensure they meet regulatory standards.
One of the primary objectives is to reduce PFAS emissions and exposure. The project will explore end-of-life management options, such as recycling and safe disposal, to minimise environmental impact. Additionally, it will focus on developing a database of PFAS alternatives and new disposal processes. These efforts are crucial for protecting both the environment and public health.
The initiative faces challenges, including the complexity of the global supply chain and the need for standardised testing protocols. However, by leveraging industry-academia collaboration, the project aims to overcome these hurdles. The EU's commitment to reducing PFAS usage aligns with broader health and environmental policies, ensuring long-term sustainability and innovation in the healthcare sector.
Official source
ec.europa.euTopics
PFAS are durable chemicals used in healthcare for their resistance to heat and chemicals, found in medical devices and packaging. However, their environmental persistence and health risks have prompted the EU to seek safer alternatives.
The EU's initiative aims to reduce PFAS emissions and develop sustainable alternatives through collaboration with industry stakeholders. This project aligns with the EU's Green Deal, focusing on environmental safety and innovation.

Dr Steven Brennan
CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.
More from Dr Steven BrennanForesight follows changes like this one and shows where they reach your substances, products and markets.

European Economic Area

European Economic Area

European Economic Area
Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.
Read by professionals at